Samuel Ogunsalu has a BSc in Microbiology, from the University of Wales, and an MSc in Biochemical Engineering, from UCL. He has over 20 years’ experience in technology commercialisation, licensing and business development. He has executed a wide number of transactions ranging from negotiating licences and M&As, to transformational technology partnerships with companies such as Merck, GSK, Pharmacia (merged with Pfizer) and Abbott (now AbbVie) as well as helping to establish preclinical research programmes with a number of industrial partners. He has also set up joint ventures, start-ups, and spinout companies to develop novel technologies. Samuel has previously been Chief Business Officer & Director of an oncology company, and Chief Commercial Officer of an Aim listed biotech company. Prior to that he has held a number of positions across technology business units connected with Queen Mary College, London, as well as other roles in which he has advised private and listed companies in both the UK and the USA. He started his professional career as a pilot plant engineer at Imperial College, London, followed by scientific research at University College London, before moving into business & commercial development. Samuel has co-founded and invested in several start-ups.